TMCnet News
Research and Markets: 2013 Report on the North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/bp9wmt/north_american) has announced the addition of the "2013 Report on the North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017" report to their offering. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 in Canada is, however, a major threat for manufacturers. The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant ide effects; radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 North American Radiopharmaceuticals Market, By Isotope 5 North American Radiopharmaceuticals Market, By Application/Indications 6 North American Enriched Stable Isotopes Market 7 Geographic Analysis 8 Competitive Landscape 9 Company Profiles Companies Mentioned:
For more information visit http://www.researchandmarkets.com/research/bp9wmt/north_american
|